3SOF

Quote from: Terliso on April 13, 2007, 01:33:04 PM
XOMA going for the 3rd wave.

3rd wave is in....  $4.50 should be a good reasonable target selling price for this pattern

update:
XOMA Gives Pfizer Rights to Patented Bacterial Cell Expression Technology


XOMA Ltd. (XOMA) announced that it has licensed to Pfizer Inc. nonexclusive,
worldwide rights to XOMA's patented bacterial cell expression
(BCE) technology for phage display and other research, development
and manufacturing of antibody products. Under the terms of the
agreement, XOMA will receive an upfront, non-dilutive cash payment
of $30 million and milestone, royalty and other fees on future sales of
all products subject to this license, including products currently in latestage
clinical development.

Xoma rocket !  Busted through the 200-day MA...

Xoma Ltd. (XOMA:xoma ltd
Last: 3.07+0.30+10.83%

3.07, +0.30, +10.8%) shares soared... The biotech company said it has licensed its bacterial cell expression technology to Pfizer Inc. (PFE:Pfizer Inc
Last: 25.08+0.24+0.97%

25.08, +0.24, +1.0%) for use in developing antibody-based treatments.
Under the deal, Xoma will receive $30 million upfront and royalties on sales of any future products that utilize the technology, including those currently in late-stage development.
Pfizer shares were fractionally lower at $24.69.

INITIATES PHASE I CLINICAL STUDY: XOMA Ltd. (XOMA) announced the start of a second
Phase 1 clinical study of XOMA 052, a potent monoclonal antibody targeting Interleukin-1 beta,
in patients with Type 2 diabetes.

travis-

How many stocks do you own?

Do you ever sell anything?

I don't understand how you can follow all these stocks. 

Quote from: bjc on September 14, 2007, 02:09:06 PM
travis-

How many stocks do you own?

Do you ever sell anything?

I don't understand how you can follow all these stocks. 

I thought I seen this question on a thread...
I own at this time 30 stocks.
Yes, I do sell from time to time.
I'm not a day trader, very seldom I may try my hand at this.
I hold short term 1 to 3 months
Mid term 3 to 6 months
Long term over 6 months to years.
How I follow all these stocks , much hard work !

Back with the closing chart on XOMA today....
Looks like we may have a Pennant (continuation) Pattern here
May get the bounce off the 13-day MA....watch err...
JMHO of course....

Holding this one for a week or two, long at 0.84... hopefully this pulls an 'AGEN', and hits 2+ tomorrow... but we'll see.

g

somewhat disappointing action friday, but news out this weekend and still holding...

g

uy now traget 2$


break 1.50$ than 2$

 

Xoma now looks ready for an entra hee 90 cent is a big support here volum now comes down...

Buyes will get in monday we could se a hammer candle or a white one!

we got a bullish reversal here lok at the cadle and the 50 retrace...

bullish engulfing



at example:



Downtrend Break volume comes in
read the news investor got in last week at 1.15$ so
lets go up!

MACD bullish bounce
RSI bullish up

Stochastic show as u negativ Differgence so should go up soon!!

and differgence said uptrend is still weee in trend

updated chart look...

Missed the pop north...I guess we got a bunch of readers..no posters 
Back above the 200-day ma

InPlay
5:02PM XOMA Limited announced that it has conducted an interim review of three-month data; XOMA 052 was shown to be well-tolerated (XOMA) 6.78 +0.11 : Co announced that it has conducted an interim review of three-month data from a Phase 2a clinical trial of XOMA 052 in a small group of 74 patients with Type 2 diabetes focused on evaluating safety where XOMA 052 was shown to be well-tolerated, the primary goal of the study. This Phase 2a trial was designed as an exploratory trial focused on overall safety and kinetics and was not designed to show statistically significant differences in measures of biological activity. XOMA 052 is being studied in an ongoing 420 patient, six month Phase 2b dose-ranging clinical trial where results are expected by the end of this quarter and the primary goal of the study is reduction in levels of hemoglobin A1c. The primary goal of the Phase 2a trial was to gain additional XOMA 052 safety information in Type 2 diabetes patients on a background of stable metformin monotherapy. In this study, XOMA 052 was well tolerated with no significant differences in adverse events, lab abnormalities and vital signs between XOMA 052 and placebo and no drug-related adverse events. At the time of this three month interim review, evidence of biological activity was observed, including a reduction in C-reactive protein levels and a modest reduction in hemoglobin A1c levels. XOMA 052 is designed to inhibit the pro-inflammatory cytokine interleukin-1 beta that is believed to be a primary trigger of pathologic inflammation in Type 2 diabetes. XOMA is jointly developing XOMA 052 in collaboration with Servier.

____________________________________________________________

Day's Range: 6.76 - 7.20
52wk Range: 2.24 - 12.60
Volume: 9,177,280
Avg Vol (3m): 3,296,330
Market Cap: 147.79M
P/E (ttm): N/A
EPS (ttm): -2.88
Div & Yield: N/A (N/A)

Technicals
Most Actives

Last Price Quote is:
25.00%above 13-day EMA
77.95%above 50-day EMA
RS Rating: 97